Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism

    Duan Linli
    Duan Linli
    Zhou Nuofu
    Zhou Nuofu
    Yan Huang
    Yan Huang
    Guo Yehui
    Guo Yehui
    Zhang Nuofu
    Zhang Nuofu
    Yang Xinyan
    Yang Xinyan
    Su Xiaofen
    Su Xiaofen

    Clinica chimica acta; international journal of clinical chemistry, 2016.

    Cited by: 0|Bibtex|Views7|Links
    WOS
    Keywords:
    CYP2C9Deep venous thrombosisPulmonary embolismRivaroxabanVKORC1

    Abstract:

    Pulmonary embolism (PE) is a life-threatening manifestation of venous thromboembolism. Rivaroxaban is an oral anticoagulant, which directly inhibits Factor Xa. The objective of the current study was, in comparison to the standard-therapy method, to investigate the potential of rivaroxaban to improve the treatment of patients with PE, and ...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments